Product Name | EAAGIGILTV |
Product Quantity | 4mg |
Catalog Number | LT8266 |
Category | MART1 |
Sequence | EAAGIGILTV |
Purity | >95% |
Product Description | The EAAGIGILTV peptide is derived from the Melan-A/MART-1 antigen, a melanoma-associated protein. Presented by HLA-A*02:01, it is recognized by CD8+ T cells and is a key target in melanoma immunotherapy. This epitope is widely used in cancer vaccine research, adoptive T cell therapies, and studies aiming to enhance anti-tumor immune responses. |
Scientific Background | EAAGIGILTV is a 10-residue synthetic peptide with the sequence Glu-Ala-Ala-Gly-Ile-Gly-Ile-Leu-Thr-Val. The sequence has a relatively high hydrophobic-residue fraction that can influence aqueous solubility and surface adsorption. These sequence-derived properties describe the reagent chemically; no specific receptor, enzyme, pathway, disease association, or biological activity is assigned without product-specific experimental evidence. |
Research Applications | - LC-MS/HPLC analytical method development
- sequence-specific assay controls
|
Experimental Notes | Sequence-derived chemical properties support reagent selection and experimental planning but do not establish biological function. Solubility, aggregation, adsorption, conjugation efficiency, and assay performance should be validated under the intended experimental conditions. |
